MX2015005891A - Formas polimórficas de suvorexant. - Google Patents

Formas polimórficas de suvorexant.

Info

Publication number
MX2015005891A
MX2015005891A MX2015005891A MX2015005891A MX2015005891A MX 2015005891 A MX2015005891 A MX 2015005891A MX 2015005891 A MX2015005891 A MX 2015005891A MX 2015005891 A MX2015005891 A MX 2015005891A MX 2015005891 A MX2015005891 A MX 2015005891A
Authority
MX
Mexico
Prior art keywords
suvoroxant
polymorphic forms
suvorexant
amorphous
processes
Prior art date
Application number
MX2015005891A
Other languages
English (en)
Inventor
Vishweshwar Peddy
Deepika Pathivada
Srinivas Enugula
Arjun Kumar H Tummala
Original Assignee
Reddys Lab Ltd Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddys Lab Ltd Dr filed Critical Reddys Lab Ltd Dr
Publication of MX2015005891A publication Critical patent/MX2015005891A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con la forma cristalina de suvorexant, con la forma amorfa de suvorexant, con la dispersión de sólidos amorfos de suvorexant, con procesos para su preparación y con formas de dosificación farmacéutica de éstas.
MX2015005891A 2012-11-12 2013-11-12 Formas polimórficas de suvorexant. MX2015005891A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN4742CH2012 2012-11-12
IN5322CH2012 2012-12-19
PCT/IB2013/060080 WO2014072961A2 (en) 2012-11-12 2013-11-12 Polymorphic forms of suvoroxant

Publications (1)

Publication Number Publication Date
MX2015005891A true MX2015005891A (es) 2015-12-09

Family

ID=50685273

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005891A MX2015005891A (es) 2012-11-12 2013-11-12 Formas polimórficas de suvorexant.

Country Status (10)

Country Link
US (1) US20160272627A1 (es)
EP (1) EP2917187A2 (es)
JP (1) JP2015536975A (es)
KR (1) KR20150097486A (es)
CN (1) CN104918920A (es)
AU (1) AU2013343027A1 (es)
CA (1) CA2890949A1 (es)
IL (1) IL238744A0 (es)
MX (1) MX2015005891A (es)
WO (1) WO2014072961A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013181174A2 (en) 2012-05-31 2013-12-05 Merck Sharp & Dohme Corp. Solid dosage formulations of an orexin receptor antagonist
WO2015158910A2 (en) * 2014-04-17 2015-10-22 Sandoz Ag Solid dispersion comprising an orexin receptor antagonist
US9969725B2 (en) 2014-04-21 2018-05-15 Merck Sharp & Dohme Corp. Pharmaceutical salts of an orexin receptor antagonist
CN105377840B (zh) * 2014-05-28 2017-12-22 杭州普晒医药科技有限公司 一种二氮杂环庚烷化合物的盐及其晶型与无定型物
CN104502499B (zh) * 2014-12-10 2016-04-20 广东东阳光药业有限公司 一种异构体的高效液相检测方法
CN104569255B (zh) * 2014-12-15 2016-04-20 广东东阳光药业有限公司 一种用HPLC测定Suvorexant中间体的方法
CZ201587A3 (cs) 2015-02-10 2016-08-17 Zentiva, K.S. Amorfní pevná forma suvorexantu s kyselinou sírovou
WO2017001499A1 (en) * 2015-06-30 2017-01-05 Hexal Ag Liquid composition comprising suvorexant
WO2017072264A1 (en) * 2015-10-29 2017-05-04 Hexal Ag Solid composition comprising suvorexant
CN107202855B (zh) * 2016-03-17 2020-08-11 广东东阳光药业有限公司 一种用hplc测定苏沃雷生及其中间体的方法
CN110818701B (zh) * 2018-08-13 2023-01-17 扬子江药业集团有限公司 一种苏沃雷生的精制方法
CN109651913A (zh) * 2019-01-15 2019-04-19 湖南康瑞涂料科技有限公司 一种水基涂料组合物
CN114344269B (zh) * 2021-12-28 2023-11-03 北京鑫开元医药科技有限公司 一种苏沃雷生片及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081229A1 (es) * 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
UA106873C2 (uk) * 2006-12-01 2014-10-27 Мерк Шарп Енд Доме Корп. Сполуки заміщених діазепанів як антагоністи орексинових рецепторів
EP2680697B1 (en) * 2011-03-03 2018-01-10 Merck Sharp & Dohme Corp. Process for the preparation of an orexin receptor antagonist

Also Published As

Publication number Publication date
US20160272627A1 (en) 2016-09-22
IL238744A0 (en) 2015-06-30
WO2014072961A2 (en) 2014-05-15
KR20150097486A (ko) 2015-08-26
JP2015536975A (ja) 2015-12-24
WO2014072961A3 (en) 2014-07-03
CN104918920A (zh) 2015-09-16
EP2917187A2 (en) 2015-09-16
AU2013343027A1 (en) 2015-06-18
CA2890949A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
MX2015005891A (es) Formas polimórficas de suvorexant.
IN2013CN09704A (es)
EP2938616A4 (en) PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES
WO2014068586A3 (en) Solid oral compositions of tolvaptan
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
HK1207397A1 (en) Purification of succinic acid
IN2013MU03641A (es)
EP2697238A4 (en) SOLID FORMS OF ANTIRETROVIRUS COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITION
PL3524260T3 (pl) Kompozycje farmaceutyczne do leczenia braku apetytu
EP2807143A4 (en) PROCESS FOR THE PREPARATION OF FINGOLIMODE
FR2985992B1 (fr) Nouveau procede de preparation de silices precitees
SI3309158T1 (sl) Rivaroksaban kristalne oblike K in postopek njegove priprave
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
AP2012006280A0 (en) Synthesis process, and crystalline form of 4-ä3-ÄCis-hexahydrocyclopentaÄCÜpyrrol-2(1H)-YLÜpropoxyübenzamide hydrochloride and pharmaceutical compositions containing it.
IN2014DN09451A (es)
IL233938A (en) A process for preparing phenylpropenones is produced
LT2939665T (lt) Farmacinė kompozicija, skirta živ infekcijų gydymui
IN2013MU03317A (es)
WO2014122671A3 (en) Solid oral compositions of saxagliptin
WO2014041558A3 (en) Process for preparation of crystalline etoricoxib
WO2013114397A3 (en) Pharmaceutically acceptable salt of brinzolamide and composition thereof
IL229669A0 (en) Process for the preparation of 1,2,3 triazole 4 carboxamide
EP2906536A4 (en) IMPROVED METHOD FOR PRODUCING A PERINDOPRIL INTERMEDIATE PRODUCT
IN2015DN02660A (es)
IN2012CH02984A (es)